FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Drugs Made In America Acquisition II Corp. Unit Stock AnalysisComprehensive stock analysis for Drugs Made In America Acquisition II Corp. Unit (DMIIU) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDMIIU
DMIIU
Drugs Made In America Acquisition II Corp. Unit
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DMIIU
Home🔹Stocks🔹Drugs Made In America Acquisition II Corp. Unit

Drugs Made In America Acquisition II Corp. Unit

DMIIU•NASDAQ

Drugs Made In America Acquisition II Corp. Unit

DMIIU•NASDAQ
Market cap
$705.87M
Sentiment

Your view on DMIIU

Mkt Cap
$705.87M
Sentiment
Your view
DMIIU
Drugs Made In America Acquisition II Corp. Unit
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DMIIU
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Drugs Made In America Acquisition II Corp. Unit

Industry
Shell Companies
Sector
Financial Services
CEO
Roger Bendelac
Headquarters
420 Lexington Avenue, New York, NY, US
Industry
Shell Companies
Sector
Financial Services
CEO
Roger Bendelac
Headquarters
420 Lexington Avenue, New York, NY, US
Description

DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing. Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Drugs Made In America Acquisition II Corp. Unit, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Drugs Made In America Acquisition II Corp. Unit. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Drugs Made In America Acquisition II Corp. Unit. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Drugs Made In America Acquisition II Corp. Unit. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Drugs Made In America Acquisition II Corp. Unit. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Drugs Made In America Acquisition II Corp. Unit valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Drugs Made In America Acquisition II Corp. Unit, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Drugs Made In America Acquisition II Corp. Unit executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Drugs Made In America Acquisition II Corp. Unit. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Drugs Made In America Acquisition II Corp. Unit. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Drugs Made In America Acquisition II Corp. Unit. Press releases and market coverage, newest first.

News

Latest Market News